Stryker Corporation $SYK Shares Purchased by Candriam S.C.A.

Posted by Francis Steltz on Jul 11th, 2026

Candriam S.C.A. raised its stake in Stryker Corporation (NYSE:SYK – Free Report) by 1.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,146 shares of the medical technology company’s stock after purchasing an additional 2,694 shares during the period. Candriam S.C.A.’s holdings in Stryker were worth $54,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in SYK. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker during the fourth quarter worth approximately $26,000. Sankala Group LLC purchased a new position in Stryker in the fourth quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Stryker in the 4th quarter valued at approximately $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.8%

Shares of Stryker stock opened at $329.86 on Friday. The company has a fifty day simple moving average of $310.12 and a 200-day simple moving average of $337.97. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a market cap of $126.46 billion, a price-to-earnings ratio of 38.18, a PEG ratio of 2.10 and a beta of 0.77.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the company earned $2.84 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is currently 40.74%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SYK. UBS Group decreased their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. BMO Capital Markets began coverage on Stryker in a research note on Wednesday. They issued an “outperform” rating and a $369.00 price target on the stock. Canaccord Genuity Group decreased their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Robert W. Baird set a $385.00 price objective on Stryker in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $392.87.

Get Our Latest Analysis on SYK

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.